文献速递肾小球疾病遗传性与小管间质肾病

羟丙基-β-环糊精在实验性Alport综合征和局灶节段性肾小球硬化中保护肾脏

Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.
PubMed 文献 · Kidney Int · 2018-10-06

研究在Col4a3敲除Alport综合征小鼠模型中发现肾皮质胆固醇含量增加8倍,伴肾小球脂滴和胆固醇结晶增多。羟丙基-β-环糊精(HPβCD)治疗降低肾脏胆固醇,减轻白蛋白尿、肾衰竭、炎症和肾小管间质纤维化;在阿霉素肾病模型中亦减少蛋白尿和系膜扩张。NEPTUNE研究患者肾小球脂质相关基因失调。

要点

  • Alport综合征小鼠肾皮质胆固醇含量增加8倍,伴脂滴和胆固醇结晶。
  • HPβCD降低肾脏胆固醇并保护肾功能,减轻白蛋白尿和纤维化。
  • 非代谢性肾小球病如Alport综合征和FSGS存在脂质代谢异常。

核心结论

  • 脂质代谢异常发生于Alport综合征和FSGS等非代谢性肾小球疾病,HPβCD改善实验性Alport综合征和FSGS的肾脏病变。

研究设计与样本

  • 研究使用Col4a3敲除Alport综合征小鼠模型和адриамицин诱导肾病模型,并分析NEPTUNE研究原发性FSGS患者肾活检肾小球的微阵列数据。

主要发现

  • Alport综合征小鼠肾皮质胆固醇含量增加8倍,伴肾小球脂滴和胆固醇结晶增多。
  • HPβCD治疗降低Alport综合征小鼠肾脏胆固醇含量,减轻白蛋白尿、肾衰竭、炎症和肾小管间质纤维化。
  • HPβCD在адриамицин诱导肾病模型中减轻蛋白尿和系膜扩张。
  • NEPTUNE研究原发性FSGS患者肾小球中多个脂质相关基因失调。

临床怎么用

  • HPβCD可能为Alport综合征和FSGS提供靶向脂质代谢的治疗策略,但尚需临床验证。

局限性

  • 证据主要来自动物模型和患者肾小球基因表达分析,缺乏人体干预试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Studies suggest that altered renal lipid metabolism plays a role in the pathogenesis of diabetic kidney disease and that genetic or pharmacological induction of cholesterol efflux protects from the development of diabetic kidney disease and focal segmental glomerulosclerosis (FSGS). Here we tested whether altered lipid metabolism contributes to renal failure in the Col4a3 knockout mouse model for Alport Syndrome. There was an eight-fold increase in the cholesterol content in renal cortexes of mice with Alport Syndrome. This was associated with increased glomerular lipid droplets and cholesterol crystals. Treatment of mice with Alport Syndrome with hydroxypropyl-β-cyclodextrin (HPβCD) reduced cholesterol content in the kidneys of mice with Alport Syndrome and protected from the development of albuminuria, renal failure, inflammation and tubulointerstitial fibrosis. Cholesterol efflux and trafficking-related genes were primarily affected in mice with Alport Syndrome and were differentially regulated in the kidney cortex and isolated glomeruli. HPβCD also protected from proteinuria and mesangial expansion in a second model of non-metabolic kidney disease, adriamycin-induced nephropathy. Consistent with our experimental findings, microarray analysis confirmed dysregulation of several lipid-related genes in glomeruli isolated from kidney biopsies of patients with primary FSGS enrolled in the NEPTUNE study. Thus, lipid dysmetabolism occurs in non-metabolic glomerular disorders such as Alport Syndrome and FSGS, and HPβCD improves renal function in experimental Alport Syndrome and FSGS.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Mitrofanova A, Molina J, Varona Santos J, et al. Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis. Kidney Int. 2018. PMID: 30301568. doi:10.1016/j.kint.2018.06.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。